What's Next For Johnson & Johnson Stock?
Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.
The Motley Fool2d
Johnson & Johnson Q3 EPS Dips on Charges
In Q3 2024, Johnson & Johnson's innovative medicine segment reported a 6.3% operational sales growth, with oncology and immunology products leading the way. Substantial demand for Darzalex and ...
Johnson & Johnson Q3: Strengthening Cardiovascular Device Portfolio
Johnson & Johnson's Q3 results exceeded expectations, with 26.5% year-over-year growth in the cardiovascular market and a 5.4 ...
What Trends Will Drive Johnson & Johnson's Q3 Results?
We expect the company to post revenue of $22.2 billion and earnings of $2.20 per share, broadly aligning with the consensus ...
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...
MM&M1d
J&J reports Q3 sales surge of 5.2% despite EPS decline due to M&A activity
Despite the topline growth, J&J’s net earnings fell 37.5% to $2.6 billion, down from $4.3 billion in Q3 2023. Johnson & ...